MDT - Medtronic plc
| Previous Close | 112.38 |
| Open | 112.06 |
| Bid | 113.14 x 800 |
| Ask | 113.93 x 800 |
| Day's Range | 111.84 - 113.89 |
| 52 Week Range | 81.66 - 114.46 |
| Volume | 3912298 |
| Avg. Volume | 4,028,052 |
| Market Cap | 152B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | 32.24 |
| EPS (TTM) | 3.52 |
| Earnings Date | Feb 18, 2020 |
| Forward Dividend & Yield | 2.16 (1.92%) |
| Ex-Dividend Date | 2019-12-26 |
| 1y Target Est | 121.90 |
- Investor's Business Daily
Diabetes Stock Nabs Key Approval; Can It Take On Giant Medtronic?
Tandem Diabetes nabbed Food and Drug Administration clearance for a new diabetes management system Friday — prodding TNDM stock to pop at the close in higher-than-average volume.
- Zacks
Minimally Invasive Surgery Gains Ground: 3 Stocks in Focus
With minimally invasive surgery gaining momentum, these stocks are poised to capitalize on the market prospects.
- Simply Wall St.
Does Medtronic plc's (NYSE:MDT) P/E Ratio Signal A Buying Opportunity?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
- Simply Wall St.
Richard Anderson Is The Independent Director of Medtronic plc (NYSE:MDT) And They Just Spent US$566k On Shares
Those following along with Medtronic plc (NYSE:MDT) will no doubt be intrigued by the recent purchase of shares by...
- American City Business Journals
Dayton investor Barry James: Three stocks to watch in 2020
The top executive at Dayton's largest money management firm said he sees value opportunities for two sectors in 2020: finance and energy.
- PR Newswire
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.
- American City Business Journals
No more finger prick? Md. biotech aims for bigger market for diabetes app.
Senseonics Holdings Inc. has slapped a new label on its blood-sugar monitoring system, a move that boils down to one thing for diabetes patients: fewer finger sticks. The Germantown company — whose implantable continuous glucose monitoring (CGM) system senses a person’s glucose levels to determine if he or she needs insulin, food or exercise — is starting to market the product as an alternative to the decades-old step of pricking a finger multiple times a day to elicit a drop of blood. Senseonics (NYSE: SENS) earned that right to market its Eversense CGM system as a replacement for finger sticks to measure glucose, per approval by the Food and Drug Administration this past summer.
- Zacks
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
- GlobeNewswire
Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2020
DUBLIN, Dec. 06, 2019 -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share,.
- Zacks
5 High-Flying Stocks Near 52-Week High With More Room to Run
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
- American City Business Journals
Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
- PR Newswire
ViewRay Announces Pricing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 6,232,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
- Zacks
The Zacks Analyst Blog Highlights: Medtronic, Apple, Stryker and Intuitive Surgical
The Zacks Analyst Blog Highlights: Medtronic, Apple, Stryker and Intuitive Surgical
- PR Newswire
ViewRay Announces Collaborations with Elekta and Medtronic
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
- Zacks
Industry 4.0 to Steer MedTech to Higher Growth: A Sneak Peek
Investors need to be bold enough to bet on trend-shifting consumption habits emanating from Industry 4.0, which will stand them in good stead.
- GuruFocus.com
Urbem's 'Wonderful Business' Series: Intuitive Surgical
A near-monopoly pioneer in a fast-growing space Continue reading...
- Zacks
Medtronic Displays All-Business-Line Growth Despite Cost Woes
Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.
- Zacks
Digital Diabetes Management Gains Momentum: 3 Stocks in Focus
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
- Zacks
Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients
Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.
- Insider Monkey
Is Medtronic plc (MDT) A Good Stock To Buy ?
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
- Zacks
Here's Why You Should Hold on to Varian (VAR) Stock for Now
Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.
- Insider Monkey
Here is 16th Most Popular Stock Among 752 Hedge Funds
At Insider Monkey, we pore over the filings of around 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this article, […]
- Simply Wall St.
Earnings Beat: Medtronic plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest quarterly earnings release from Medtronic plc (NYSE:MDT), an important milestone in the...
- GlobeNewswire
Medtronic Drug-Coated Balloon Receives U.S. FDA Approval to Treat Arteriovenous Fistula Lesions
Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD.
- Thomson Reuters StreetEvents
Edited Transcript of MDT earnings conference call or presentation 19-Nov-19 1:00pm GMT
Q2 2020 Medtronic PLC Earnings Call
